Imprecise information on significance of gene variants diminishes value of genetic panel testing
the ONA take:
Advances in technology provide people with the option of undergoing multigene testing, or panel testing, to determine their risk for developing various cancers.
However, an international consortium of authors caution clinicians about using these tests. Although the tests are helpful in identifying genetic mutations with the potential to increase a woman’s risk for breast and other cancers, clinicians need to be aware of, and share with patients, the limitations of test results.
Panel testing covers more than 100 genes, 21 of which are associated with breast cancer. Information about many genetic variants is lacking, and positive results may cause undue stress and anxiety over benign conditions.
In addition, patients may take significant or unnecessary risk-reducing interventions or screenings based on limited information.
The authors acknowledge that there is a significant body of evidence to support clinical action when some genetic variants are identified, such as BRCA1 and BRCA2 gene mutations; however, the implications of many other mutations are too imprecise and require further investigation.
They recommend that patients should be informed of the potential for uncertainty regarding the results.
Advances in technology provide people with the option of undergoing multigene testing determine their risk for developing cancer.
- FDA Grants Approval to Bevacizumab-awwb as First Biosimilar for Anticancer Therapy
- Efficacy of Octreotide LAR, Lanreotide in Management of Carcinoid Tumors
- Multivitamin Use May Reduce Risk of Chemo-Induced Neuropathy
- Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination
- Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC
- Invisible Burdens: The Complex Needs of Caregivers of Patients With Brain Cancer
- Cannabis Reduces Response Rate to Immunotherapy for Cancer
- Perioperative Blockade of Pathways May Improve Outcomes in Breast Cancer
- Zika Virus Preferentially Targets Glioblastoma Stem Cells
- Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications
- Lorazepam Plus Haloperidol Improves Agitation in Cancer-Related Delirium
- Cost of Care Significantly Increased With Carcinoid Syndrome in NETs
- Treating Intractable Hiccups in Advanced Cancer, Palliative Care Setting
- Severe Mental Illness May Worsen Breast Cancer Survival Outcomes
- Imaging Management of Breast Density, a Controversial Risk Factor for Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|